Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Metabolic Disorders

Set Alert for Metabolic Disorders

Pfizer And ProFound Partner On Next-Generation Obesity Drugs

Deal Snapshot: Pfizer will collaborate with the Flagship Pioneering-backed startup under a broader long-term partnership between the big pharma and venture capital firm.

Deals Innovation

Syntis Bio Launches, Focusing On Oral Obesity Drugs And Rare Diseases

The company formed around technology from the labs of MIT’s Robert Langer and Giovanni Traverso and already has a lead asset in the clinic.

StartUps and SMEs Financing

Skye Bioscience Looks To Build Appetite For CB1 Obesity Drug

The company will take on Novo Nordisk in reviving the CB1 inhibitor mechanism to develop a more tolerable long-term weight loss drug, after exiting ophthalmology.

Companies Clinical Trials

EASL: Sagimet Pill Is Overlooked But Could Make A Splash In MASH

While injectables have had all the limelight, some analysts see a bright future for Sagimet’s oral denifanstat, potentially as a backbone therapy in combination with other treatments for MASH.

Clinical Trials Liver & Hepatic

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: BIO Notebook; ASCO roundup; data on Carvykti in community at ASCO; strong new results for tirzepatide in MASH; and orphan slowdown signals new path ahead.

Commercial Clinical Trials

Biomea’s Novel Diabetes Candidate Placed On FDA Hold

Biomea reported that the FDA placed a clinical hold on two ongoing Phase I/II diabetes studies of menin inhibitor BMF-219 due to concerns about liver toxicity.

Clinical Trials Business Strategies

Boehringer Backs Up Best-In-Class MASH Claims With Fibrosis Data

Survodutide burnishes its best-in-class MASH case with a 64% improvement in moderate-to advanced fibrosis at Phase II, but tolerability an issue

Clinical Trials Metabolic Disorders

Leftfield Obesity Mechanism Hurts Shionogi

When it comes to weight loss drug development, the sensible move is to follow the pack.

Clinical Trials Metabolic Disorders

EASL: Tirzepatide Is The One To Beat In MASH

An important mid-stage trial succeeds, but an odd finding on the fibrosis endpoint will spur close examination of Lilly’s incretin.

Clinical Trials Metabolic Disorders

Structure Therapeutics Aims For Best-In-Class Oral Incretin

Phase II data are positive but early, and drawing any big conclusions might be premature.

Clinical Trials Metabolic Disorders

Early Results Erode Belief In Biohaven’s Protein Degrader

Phase I results from BHV-1300 underwhelmed investors, but Biohaven is moving ahead and has many more shots on goal in protein degradation and beyond.

Clinical Trials Companies

Lilly Commits Another $5.3bn To Tirzepatide Supply Expansion Effort

Lilly is now spending about $9bn total to bring an Indiana manufacturing site for tirzepatide to readiness, although it is not expected to supply finished product until 2026.

Manufacturing Business Strategies
See All
UsernamePublicRestriction

Register